...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

** BETonMACE Phase 3 Cardio Outcomes Trial for Apabetalone Has Reached its Targeted 250 MACE Events ** Top-Line Data Expected Mid-Year 2019 https://clinicaltrials.gov/ct2/show/NCT02586155

Message: AGM 2018 - Masila Notes

"Apparently all patients interviewed want to stay on the treatment.  Some have been on close to 36 months.  That speaks volumes to me! '

You must admit, however, that the statement "That speaks volumes to me" may be misconstrued to mean that the patients interviewed were on the Apabetalone treatment when they wouldn't have known which treatment they were on. Perhaps this is what DND was getting at.

And what does all patients mean? How many were actually interviewed?


Just saying...Koo


New Message
Please login to post a reply